BIOGEN INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 224.9 USD | +2.21% |
|
+3.27% | -13.07% |
| May. 31 | Biogen: Brussels grants marketing authorization for Charcot disease | CF |
| May. 31 | Disaster averted |  |
Financials (USD)
| Sales 2024 * | 9.52B | Sales 2025 * | 9.56B | Capitalization | 32.75B |
|---|---|---|---|---|---|
| Net income 2024 * | 1.92B | Net income 2025 * | 2.24B | EV / Sales 2024 * | 3.75 x |
| Net Debt 2024 * | 2.99B | Net Debt 2025 * | 614M | EV / Sales 2025 * | 3.49 x |
| P/E ratio 2024 * |
17.4
x | P/E ratio 2025 * |
14.9
x | Employees | 7,570 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 85.81% |
More Fundamentals
* Assessed data
More news
Latest transcript on Biogen Inc.
More recommendations
More press releases
More news
| 1 day | +2.21% | ||
| 1 week | +3.27% | ||
| 1 month | +4.71% | ||
| 3 months | +3.66% | ||
| 6 months | -3.90% | ||
| Current year | -13.07% |
1 week
210.33
225.59
1 month
210.33236.90
Current year
189.44268.30
1 year
189.44319.76
3 years
187.16468.55
5 years
187.16468.55
10 years
187.16480.18
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 64 | 22-11-13 | |
| Director of Finance/CFO | 60 | 20-08-14 | |
Nicole Murphy
COO | Chief Operating Officer | - | 14-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Stephen Sherwin
BRD | Director/Board Member | 75 | 09-12-31 |
William Hawkins
BRD | Director/Board Member | 70 | 19-06-18 |
Caroline Dorsa
CHM | Chairman | 64 | 10-01-02 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 4.30% | 1 M€ | -.--% | - | |
| 3.92% | 0 M€ | 0.00% | - | |
| 3.75% | 0 M€ | 0.00% | - | |
| 2.39% | 13,519 M€ | +3.20% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-31 | 224.9 | +2.21% | 1,872,380 |
| 24-05-30 | 220.1 | +2.64% | 939,978 |
| 24-05-29 | 214.4 | -1.98% | 980,438 |
| 24-05-28 | 218.7 | +0.42% | 633,178 |
| 24-05-24 | 217.8 | -0.11% | 770,943 |
Delayed Quote Nasdaq, May 31, 2024 at 04:00 pm EDT
More quotes
Biogen Inc. is one of the world's leaders in the design, manufacturing, and marketing of therapeutic products. Net sales break down by source of income as follows:
- sales of medicines (73,7%): for treating multiple sclerosis, chronic psoriasis in adults, rheumatoid arthritis, cancers, etc.;
- royalties (17,2%) ;
- other (9,1%): primarily revenues from partnership agreements.
Sector
Pharmaceuticals
Calendar
2024-06-20
- Annual General Meeting
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
BUY
Number of Analysts
34
Last Close Price
224.9
USD
Average target price
284.8
USD
Spread / Average Target
+26.60%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -13.07% | 32.75B | |
| -2.29% | 89.87B | |
| -3.95% | 37.57B | |
| +63.05% | 26.47B | |
| -22.14% | 14.25B | |
| -7.96% | 12.99B | |
| -9.33% | 11.93B | |
| -46.33% | 10.84B | |
| +5.77% | 9.11B | |
| -17.66% | 7.32B |
- Stock Market
- Equities
- BIIB Stock
